Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199320 | 0.78 | PTPN1 (0.34) | PTPN1GLANPSR1TSHRALDH1A1 | |
| SCHEMBL905485 | 0.76 | PTPN1 (0.33) | PTPN1GLANPSR1ALDH1A1 | |
| SCHEMBL8231337 | 0.74 | GLA (0.33) | PTPN1GLANPSR1 | |
| SCHEMBL22038548 | 0.74 | GLA (0.33) | PTPN1GLANPSR1ALDH1A1 | |
| SCHEMBL17070911 | 0.72 | ALDH1A1 (0.40) | PTPN1GLANPSR1TSHRALDH1A1 | |
| SCHEMBL10922922 | 0.72 | — | — | |
| SCHEMBL21726168 | 0.71 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL21726167 | 0.71 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL13145363 | 0.71 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL146063 | 0.70 | GLA (0.37) | PTPN1GLANPSR1BACE1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012021446-A2 | PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-02-16 | — | — | WO | claimed |
| US-11693163-B2 | Optical filter and imaging device | AGC Inc. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20190049838-A1 | Photosensitive Microcapsules | ENCAPSYS, LLC | 2019-02-14 | — | — | US | disclosed |
| WO-2012021446-A2 | PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021446-A2 | PROCESS FOR PREPARING ALISKIREN AND ITS INTERMEDIATES | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-02-16 | — | — | WO | disclosed |
| EP-0393786-B1 | New retro-inverse, one- or more bond bearing analogues of thymopentin, a method for synthesizing the same and their employment for the preparation of pharmaceutical | SCLAVO SPA (IT) | 1996-01-17 | — | — | EP | disclosed |
| EP-0578849-B1 | Process for the preparation of 1,3-dioxane-4,6-dione derivates | BIOGAL GYOGYSZERGYAR (HU) | 1995-05-17 | — | — | EP | disclosed |
| US-5350872-A | Decyclization and decarboxylation of a 1,3-dioxane-4,6-dione | BIOGAL GYOGYSZERGRAR (HU) | 1994-09-27 | — | — | US | disclosed |
| EP-0375058-B1 | New retro-inverso analogues of trymopentin, the method for their synthesis and their use in the preparation of pharmaceutical compositions | SCLAVO SPA (IT) | 1994-03-16 | — | — | EP | disclosed |
| EP-0578849-A1 | Process for the preparation of 1,3-dioxane-4,6-dione derivates | BIOGAL GYOGYSZERGYAR (HU) | 1994-01-19 | — | — | EP | disclosed |
| EP-0578850-A1 | Process for the preparation of carboxylic acids and derivatives of them | BIOGAL GYOGYSZERGYAR (HU) | 1994-01-19 | — | — | EP | disclosed |
| US-5218089-A | Retro-inverso analogues of thymopentin and the method for their synthesis | SCLAVO S.P.A. (IT) | 1993-06-08 | — | — | US | disclosed |
| US-5091510-A | Tetrapeptides of Arg, Lys, Asp and Val | SCALVO, S.P.A. (IT) | 1992-02-25 | — | — | US | disclosed |
| EP-0393786-A1 | New retro-inverse, one- or more bond bearing analogues of thymopentin, a method for synthesizing the same and their employment for the preparation of pharmaceutical | SCLAVO S.p.A. (IT) | 1990-10-24 | — | — | EP | disclosed |
| EP-0375058-A2 | New retro-inverso analogues of trymopentin, the method for their synthesis and their use in the preparation of pharmaceutical compositions | SCLAVO S.p.A. (IT) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PTPN1 2215/4885GLA 2345/4885NPSR1 3519/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PTPN1 2215/4885GLA 2345/4885NPSR1 3519/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | PTPN1 1073/4885GLA 2219/4885NPSR1 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.